Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes

J Immunol. 2001 Aug 1;167(3):1821-9. doi: 10.4049/jimmunol.167.3.1821.

Abstract

The exclusive detrimental role of proinflammatory cytokines in demyelinating diseases of the CNS, such as multiple sclerosis, is controversial. Here we show that the intrathecal delivery of an HSV-1-derived vector engineered with the mouse IFN-gamma gene leads to persistent (up to 4 wk) CNS production of IFN-gamma and inhibits the course of a chronic-progressive form of experimental autoimmune encephalomyelitis (EAE) induced in C57BL/6 mice by myelin oligodendrocyte glycoprotein (MOG)(35-55). Mice treated with the IFN-gamma-containing vector before EAE onset showed an earlier onset but a milder course of the disease compared with control mice treated with the empty vector. In addition, 83% of IFN-gamma-treated mice completely recovered within 25 days post immunization, whereas control mice did not recover up to 60 days post immunization. Mice treated with the IFN-gamma-containing vector within 1 wk after EAE onset partially recovered from the disease within 25 days after vector injection, whereas control mice worsened. Recovery from EAE in mice treated with IFN-gamma was associated with a significant increase of CNS-infiltrating lymphocytes undergoing apoptosis. During the recovery phase, the mRNA level of TNFR1 was also significantly increased in CNS-infiltrating cells from IFN-gamma-treated mice compared with controls. Our results further challenge the exclusive detrimental role of IFN-gamma in the CNS during EAE/multiple sclerosis, and indicate that CNS-confined inflammation may induce protective immunological countermechanisms leading to a faster clearance of encephalitogenic T cells by apoptosis, thus restoring the immune privilege of the CNS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD / biosynthesis
  • Apoptosis / genetics
  • Apoptosis / immunology*
  • Blood-Brain Barrier / genetics
  • Blood-Brain Barrier / immunology
  • Brain / immunology*
  • Brain / metabolism
  • Brain / pathology
  • Cell Movement / genetics
  • Cell Movement / immunology*
  • Cerebral Ventricles / immunology
  • Cerebral Ventricles / virology
  • Chronic Disease
  • Cisterna Magna
  • Disease Progression
  • Encephalomyelitis, Autoimmune, Experimental / genetics
  • Encephalomyelitis, Autoimmune, Experimental / immunology*
  • Encephalomyelitis, Autoimmune, Experimental / pathology
  • Encephalomyelitis, Autoimmune, Experimental / prevention & control*
  • Female
  • Genetic Vectors / administration & dosage
  • Herpesvirus 1, Human / genetics
  • Injections
  • Injections, Spinal
  • Interferon-gamma / administration & dosage*
  • Interferon-gamma / biosynthesis
  • Interferon-gamma / genetics
  • Lymphocyte Count
  • Lymphocyte Subsets / immunology
  • Lymphocyte Subsets / metabolism
  • Lymphocyte Subsets / pathology*
  • Mice
  • Mice, Inbred C57BL
  • Receptors, Tumor Necrosis Factor / biosynthesis
  • Receptors, Tumor Necrosis Factor, Type I
  • Spinal Cord / immunology*
  • Spinal Cord / metabolism
  • Spinal Cord / pathology
  • Subarachnoid Space / immunology
  • Subarachnoid Space / virology
  • Virus Replication / genetics

Substances

  • Antigens, CD
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type I
  • Interferon-gamma

Grants and funding